Robert Marshall
About Robert Marshall
Robert Marshall, 59, is an independent Class III director at Lifeward (LFWD) since November 2024 and serves as Chair of the Audit Committee. He is CFO and Treasurer of Lantheus Holdings (radiopharmaceuticals) since September 2018; previously he spent 16 years at Zimmer Biomet in senior finance roles, and earlier worked at Brown & Williamson. He holds an MBA from Indiana University (South Bend), a BBA in Finance from the University of Notre Dame, and is a CFA charterholder .
Past Roles
| Organization | Role | Tenure/Details | Committees/Impact |
|---|---|---|---|
| Lifeward Ltd. | Independent Director (Class III), Audit Committee Chair | Director since Nov 2024; Audit Chair in 2025 | Chairs Audit Committee; committee met 5x in FY2024 |
| Lantheus Holdings, Inc. | CFO & Treasurer | Since Sep 2018 | Public-company CFO; financial reporting oversight |
| Zimmer Biomet Holdings, Inc. | Various senior finance roles (incl. VP, Investor Relations & Corporate Treasurer; VP, Americas Finance) | 16 years | Large-cap medtech finance leadership |
| Brown & Williamson (BAT subsidiary) | Finance roles | Prior to Zimmer Biomet | Finance and increasing responsibility roles |
External Roles
| Company | Type | Role | Public Company Directorship? |
|---|---|---|---|
| Lantheus Holdings, Inc. | Public radiopharmaceutical company | CFO & Treasurer | No (executive, not a director) |
No other public company directorships or interlocks disclosed for Marshall. The company reports no compensation committee interlocks during the last fiscal year .
Board Governance
- Independence: The Board determined all current directors other than the two executives (co-CEOs) are independent under Nasdaq rules; this includes Robert Marshall .
- Committee assignments: Audit Committee Chair; members are Marshall (Chair), Dr. John W. Poduska and Hadar Levy; all are independent and financially literate. Marshall is designated an “audit committee financial expert” under SEC rules .
- Audit Committee activity: Audit Committee met 5 times in FY2024 and issued the Audit Committee Report recommending inclusion of 2024 audited financials; the report is signed by Robert Marshall as Chair .
- Attendance/engagement: Board held 13 meetings in FY2024; all then‑incumbent directors except Hadar Levy attended at least 75% of Board and committee meetings. The Board regularly holds executive sessions of independent directors .
- Executive sessions: Independent directors meet without management; Board has a Code of Ethics and insider trading policy .
Fixed Compensation
| Director | Period | Fees Earned in Cash ($) | Stock Awards ($) | Total ($) |
|---|---|---|---|---|
| Robert Marshall | FY2024 | 8,164 | — | 8,164 |
Breakdown (FY2024): $3,710 portion of annual retainer; $2,528 meeting fees; $1,926 audit committee member fee. Marshall joined the Board on Nov 2, 2024; amounts are prorated .
Performance Compensation
Director equity policy (non-employee directors):
- Initial RSU Award upon appointment: $50,000 grant-date value; vests in four equal quarterly installments starting 3 months after grant; accelerates upon certain change-of-control events per policy .
- Annual RSU Award: $50,000 grant-date value; vests quarterly similar to initial award; may be paid in cash/equity at committee discretion to preserve cash/equity pools .
As of Dec 31, 2024, Marshall had no outstanding RSUs/options in the non-employee director table (“—”). This aligns with the fact that the 2014 equity plan expired on Aug 19, 2024 and the 2024 plan had not been approved at that time, limiting new grants until a new plan is adopted .
| Item | Amount/Status |
|---|---|
| Initial RSU Award (policy) | $50,000; quarterly vesting |
| Annual RSU Award (policy) | $50,000; quarterly vesting |
| Marshall outstanding director equity at 12/31/2024 | None shown (“—”) |
| Plan status | 2014 plan expired Aug 19, 2024; 2024 plan not approved; 2025 plan proposed with 1.5M shares |
No director performance metrics (e.g., TSR/EBITDA targets) apply to director RSUs; they are time‑based .
Other Directorships & Interlocks
- No public company board seats for Marshall disclosed; he is a public-company CFO (Lantheus) .
- Compensation Committee interlocks: None reported during the last fiscal year .
- Related-party transactions: The company discloses related party approvals under Israeli law; no related transactions are disclosed involving Marshall since Jan 1, 2023 .
Expertise & Qualifications
- Designated Audit Committee Financial Expert; financial sophistication under Nasdaq rules .
- Extensive public-company finance experience (CFO/Treasurer at Lantheus; senior finance at Zimmer Biomet) with capital markets and investor relations background .
Equity Ownership
| Holder | Beneficial Ownership (Shares) | % of Outstanding |
|---|---|---|
| Robert Marshall | — (less than 1%) | <1% |
Notes:
- Table footnote indicates Marshall appointed Nov 2, 2024; individual share count not listed; beneficial ownership reported as less than 1% as of June 23, 2025 .
- The director equity table shows no outstanding options/RSUs for Marshall as of Dec 31, 2024 .
- No pledging or hedging by Marshall is disclosed; the company maintains an insider trading policy and code of ethics .
Governance Assessment
Strengths
- Independent director with strong financial credentials; designated audit committee financial expert and serving as Audit Committee Chair .
- Active committee oversight: Audit Committee met 5x in FY2024; issued formal report; independence of auditor discussed per PCAOB requirements .
- Board independence and governance practices affirmed; regular executive sessions; Code of Ethics and insider trading policy in place .
Watch items / potential investor attention points
- Ownership alignment: As of Jun 23, 2025, Marshall’s beneficial ownership is less than 1% with no director RSUs shown at 12/31/2024, reflecting timing constraints from plan expiry and delayed plan approval; equity alignment may increase once the 2025 plan is implemented and standard director RSU grants can resume .
- Time commitments: Full‑time CFO role at Lantheus may require ongoing monitoring for bandwidth; no conflicts or related‑party dealings disclosed to date .
Red flags
- None disclosed specific to Marshall: no related‑party transactions, no Section 16(a) delinquencies noted for him (one late filing was noted for another director), and independence affirmed .